Concepedia

Author

Robert Chen

City Of Hope National Medical CenterORCID

Also Known As

Chen,Ran, Franco Cavalli, R. Chen, R. N.S. Chen, Robert Chen

172

Publications

8.5K

Citations

39

H-Index

41

Concepts

All Affiliations

City Of Hope National Medical CenterCity of HopeThe University of Texas MD Anderson Cancer CenterSeagen (United States)Memorial Sloan Kettering Cancer Center
RC

About

Robert Chen is an author at City Of Hope National Medical Center specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

17

2.4K

2

Immunology

13

13

2.1K

3

Health Sciences

6

6

272

4

Cellular Therapies

3

3

211

5

Blood Transplantation

2

2

47

Robert Chen

×

60

Publications

8.2K

Citations

39

H-Index

YearCitations

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith,

Journal of Clinical Oncology

2012

1.5K

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale,

Journal of Clinical Oncology

2017

967

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus,

New England Journal of Medicine

2017

738

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Ajay K. Gopal, Scott E. Smith,

Blood

2016

389

Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk

Soumya Raychaudhuri, Brian Thomson, Elaine F. Remmers,

Nature Genetics

2009

350

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee,

Blood

2019

326

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Ariela Noy, Sven de Vos, Catherine Thiéblemont,

Blood

2017

283

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Ajay K. Gopal, Robert Chen, Scott E. Smith,

Blood

2014

221

CD30 Downregulation, MMAE Resistance, and <i>MDR1</i> Upregulation Are All Associated with Resistance to Brentuximab Vedotin

Robert Chen, Jessie Hou, Edward M. Newman,

Molecular Cancer Therapeutics

2015

202

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Alex F. Herrera, Matthew Mei, Lawrence K. Low,

Journal of Clinical Oncology

2016

185

Page 1